A novel next‐generation FVIIIa mimetic, Mim8, has a favorable safety profile and displays potent pharmacodynamic effects: Results from safety studies in cynomolgus monkeys - Lauritzen - 2022 - Journal of Thrombosis and
Pharmaceuticals | Free Full-Text | Updates on Novel Non-Replacement Drugs for Hemophilia
Novo Nordisk's Mim8 Shows Potential As Once Monthly Treatment For Hemophilia A
Novo Nordisk grows GLP-1 market share in Q2 in the US with Ozempic® and Rybelsus® - MidgardFinance.com
ISTH 2022 – Novo moves forward with its Hemlibra rival - Medical Buyer
Novo Nordisk outlines strategy for revamped rare diseases unit | BioWorld
Summer 2022 haemophilia trial update - European Pharmaceutical Review
Emerging drugs for hemophilia A: insights into phase II and III clinical trials
A factor VIIIa–mimetic bispecific antibody, Mim8, ameliorates bleeding upon severe vascular challenge in hemophilia A mice - ScienceDirect
A Novel Next-Generation FVIII Mimetic, Mim8, Has a Favourable Safety Profile. Results from a 26-Week Safety Study in Cynomolgus Monkeys - ScienceDirect
A factor VIIIa–mimetic bispecific antibody, Mim8, ameliorates bleeding upon severe vascular challenge in hemophilia A mice - ScienceDirect
Hemophilia Clinical Research Trials | CenterWatch
Marianne Kjalke's research works | Novo Nordisk, Copenhagen and other places
Novo Nordisk A/S: Mim8 phase 1 & 2 data demonstrates
